1
Orphan Designations
0 approved, 1 designated
0
FDA Approvals
0
Active Trials
180 recruiting
2
Rare Diseases
across 4 areas
0
News (30d)
Quiet
Baxter Healthcare Corporation, Baxter BioScience is a company with 1 orphan drug designation across 2 rare diseases.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| hemophilia A | Inhibitor of Tissue Factor Pathway Inhibitor (TFPI) | Des.TrialAppr. |
| hemophilia B | Inhibitor of Tissue Factor Pathway Inhibitor (TFPI) | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
17
overlap in 2+ diseases
0/2
candidate diseases
0
avg importance: 0
0
affecting portfolio
0% of portfolio targets high unmet need diseases
17
overlap in 2+ diseases
0/2
candidate diseases
0
avg importance: 0
0
affecting portfolio